SutroVax

OverviewSuggest Edit

SutroVax is a company that develops conjugate and novel complex antigen-based vaccines intended to prevent serious infectious diseases. SutroVax's cell-free protein synthesis platform permits site-specific conjugation, enabling the creation of conjugate vaccines with the potential to deliver heightened immunity and broader protection.
TypePrivate
Founded2013
HQFoster City, CA, US
Websitesutrovax.com

Latest Updates

Employees (est.) (Nov 2021)89(-2%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at SutroVax

Kurt von Emster

Kurt von Emster

Chairman
Grant Pickering

Grant Pickering

Co-Founder, President, Chief Executive Officer, Director
Carlos Paya

Carlos Paya

Former Chief Executive Officer, President, Immune Design Corp
Jim Wassil

Jim Wassil

Chief Operating Officer
Peter Hirth

Peter Hirth

Director
Halley Gilbert

Halley Gilbert

Chief Legal Officer, NeoGenomics, Inc.
Show more

SutroVax Office Locations

SutroVax has an office in Foster City
Foster City, CA, US (HQ)
353 Hatch Dr
Show all (1)

SutroVax Financials and Metrics

Summary Metrics

Founding Date

2013

SutroVax total Funding

$281 m

SutroVax latest funding size

$110 m

Time since last funding

2 years ago

SutroVax investors

SutroVax's latest funding round in March 2020 was reported to be $110 m. In total, SutroVax has raised $281 m
Show all financial metrics

SutroVax Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

SutroVax Online and Social Media Presence

Embed Graph

SutroVax News and Updates

Eyeing the most lucrative vaccine market, SutroVax nabs $85M and Moncef Slaoui as chairman

With ambitions to take on global vaccine leaders in the industry's top field, SutroVax is revving up operations with Series C funding and a prominent Big Pharma ex as chair. The target? Pneumococcal vaccines such as Pfizer’s Prevnar.

Corporate Investment In Pharma Startups On The Rebound

Many of the most active investors in pharmaceutical startups are venture capital firms such as OrbiMed Advisors, NEA, or Versant Ventures. But direct investment from corporate entities and corporate venture arms has been trending up for the past 4 years. These … Continued

SutroVax Blogs

Vaxcyte to Present at Upcoming Investor Conferences

FOSTER CITY, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today

Vaxcyte to Present at Guggenheim 2nd Annual Vaccine and Infectious Disease Conference

FOSTER CITY, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today

Vaxcyte to Present at 2021 Cantor Virtual Global Healthcare Conference

FOSTER CITY, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today

Vaxcyte Appoints Annie Drapeau and Teri Loxam to Its Board of Directors

Vaxcyte Appoints Annie Drapeau and Teri Loxam to Its Board of Directors Content Import Mon, 09/20/2021 - 16:30 Vaxcyte Appoints Annie Drapeau and Teri Loxam to Its Board of Directors Sep 20, 2021 This release is a backfill from a News Wire …

Vaxcyte Reports Second Quarter 2021 Financial Results and Provides Business Update

FOSTER CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today

Vaxcyte to Present at the Jefferies Virtual Healthcare Conference

FOSTER CITY, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today
Show more

SutroVax Frequently Asked Questions

  • When was SutroVax founded?

    SutroVax was founded in 2013.

  • Who are SutroVax key executives?

    SutroVax's key executives are Kurt von Emster, Grant Pickering and Carlos Paya.

  • How many employees does SutroVax have?

    SutroVax has 89 employees.

  • Who are SutroVax competitors?

    Competitors of SutroVax include Livzon Pharmaceutical Group, Cipla and Genentech.

  • Where is SutroVax headquarters?

    SutroVax headquarters is located at 353 Hatch Dr, Foster City.

  • Where are SutroVax offices?

    SutroVax has an office in Foster City.

  • How many offices does SutroVax have?

    SutroVax has 1 office.